Atrial Fibrillation Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Non-pharmacological, Pharmacological, Others), By End User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others) and Region Forecast 2019-2030

Atrial fibrillation market size was valued at US$ 1,945.6 million in 2023 and is poised to grow at a significant CAGR of 7.2% from 2024-2030. Atrial fibrillation is the most common problem with the heartbeat's rate or rhythm. Atrial fibrillation is caused by disordered signals that cause the two top chambers of the heart (the atria) to squeeze very quickly and out of sync. The increased prevalence of heart attacks and high blood pressure among people is driving the atrial fibrillation industry. Furthermore, the market is also boosted by the prevalence of obesity, diabetes, and metabolic syndrome. The market is predicted to develop due to the growing patient pool and the geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure.

The key players are manufacturing advanced catheter ablation for the treatment of atrial fibrillation and reducing the risk of stroke in patients, which has paved the way for lucrative opportunities in the industry. A favorable regulatory scenario would also propel growth in this market. Due to an increase in the adoption of cardiac monitoring systems during the treatment of atrial fibrillation, the surgical segment generated the most revenue in 2020. By end-user, the hospital segment registered the highest revenue in 2021, owing to the increased adoption of laser and radiofrequency methods for catheter ablation. An increase in the number of patients with arrhythmia or an irregular heartbeat problem has resulted in a growth in demand for cardiac monitors.

Key Developments 

• In Feb 2022, Boston Scientific Corporation announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths, and dilators used to support catheter-based left-heart procedures.
• In Jan 2022, Medtronic plc, a global leader in healthcare technology, announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).